The company states: “Castle Bioscience announced new data showing the ability of its pipeline test in development to distinguish between responders and non-responders to an atopic dermatitis (AD) therapy and also distinguish between AD, psoriasis (PSO) and mycosis fungoides (MF) skin lesions. The goal of Castle’s innovative pipeline initiative is to develop a genomic test aimed at guiding systemic therapy selection for patients with moderate-to-severe AD, PSO and related conditions. Additional updates regarding development of this pipeline program are expected in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CSTL:
- Castle Biosciences to share portfolio of GEP tests at FC23
- Castle Biosciences management to meet virtually with Stephens
- Castle Biosciences announces publication of TissueCypher test data
- Castle Biosciences gets ‘NY Laboratory Permit’ for Pittsburgh facility
- Castle Biosciences management to meet with KeyBanc
